StocksFundsScreenerSectorsWatchlists
IBIO

IBIO - iBio Inc Stock Price, Fair Value and News

2.06USD+0.07 (+3.52%)Market Closed

Market Summary

IBIO
USD2.06+0.07
Market Closed
3.52%

IBIO Stock Price

View Fullscreen

IBIO RSI Chart

IBIO Valuation

Market Cap

7.2M

Price/Earnings (Trailing)

-0.26

Price/Sales (Trailing)

2.14

Price/Free Cashflow

-0.38

IBIO Price/Sales (Trailing)

IBIO Profitability

Return on Equity

-296.66%

Return on Assets

-80.2%

Free Cashflow Yield

-263.15%

IBIO Fundamentals

IBIO Revenue

Revenue (TTM)

2.1M

IBIO Earnings

Earnings (TTM)

-27.3M

Earnings Growth (Yr)

75.53%

Earnings Growth (Qtr)

-42.9%

Breaking Down IBIO Revenue

Last 7 days

-2.4%

Last 30 days

77.6%

Last 90 days

76.1%

Trailing 12 Months

89.0%

How does IBIO drawdown profile look like?

IBIO Financial Health

Current Ratio

0.91

IBIO Investor Care

Shares Dilution (1Y)

463.38%

Diluted EPS (TTM)

-10.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20222.5M2.1M00
20213.0M2.4M2.0M1.5M
20201.3M1.6M1.9M2.3M
20191.3M2.0M2.1M1.7M
2018500.0K444.0K367.0K865.0K
2017522.0K394.0K381.0K459.0K
2016989.0K948.0K923.0K864.0K
20151.4M1.9M1.2M959.0K
20140205.0K616.5K1.0M
2013741.1K1.0M00
20121.1M1.3M1.3M1.1M
20110520.1K709.3K898.5K

Tracking the Latest Insider Buys and Sells of iBio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 01, 2023
brenner martin
sold
-1,295
0.2655
-4,881
see remarks
Oct 03, 2023
brenner martin
sold
-1,591
0.3022
-5,267
see remarks
Oct 02, 2023
brenner martin
sold
-1,310
0.311
-4,215
see remarks
Aug 28, 2023
brenner martin
sold
-1,528
0.3051
-5,011
see remarks
Jul 27, 2023
brenner martin
sold
-2,307
0.511091
-4,515
see remarks
Jul 12, 2023
brenner martin
sold
-27,520
0.5853
-47,020
see remarks
Jun 26, 2023
brenner martin
acquired
-
-
75,833
see remarks
Jun 22, 2023
brenner martin
back to issuer
-
-
-75,833
see remarks
Jun 21, 2023
brenner martin
sold
-2,848
0.680898
-4,184
see remarks
May 22, 2023
brenner martin
sold
-3,910
0.935057
-4,182
see remarks

1–10 of 39

Which funds bought or sold IBIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
CITY HOLDING CO
unchanged
-
11.00
16.00
-%
Apr 10, 2024
SOA Wealth Advisors, LLC.
unchanged
-
35.00
53.00
-%
Mar 11, 2024
VANGUARD GROUP INC
sold off
-100
-76,166
-
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-10,000
-
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-243
-
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
new
-
55.00
55.00
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
34,780
34,780
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
new
-
69.00
69.00
-%
Feb 14, 2024
Royal Bank of Canada
new
-
-
-
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-
-
-%

1–10 of 40

Are Funds Buying or Selling IBIO?

Are funds buying IBIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IBIO
No. of Funds

Unveiling iBio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 09, 2024
opaleye management inc.
7.63%
650,000
SC 13G/A
Apr 08, 2024
opaleye management inc.
7.63%
650,000
SC 13G
Apr 05, 2024
adar1 partners, lp
9.27%
789,293
SC 13G
Apr 01, 2024
lynx1 capital management lp
9.99%
878,492
SC 13G
Feb 13, 2024
vanguard group inc
0.23%
8,439
SC 13G/A
Jan 04, 2024
sabby management, llc
9.99%
200,303
SC 13G
Feb 09, 2023
vanguard group inc
5.28%
475,593
SC 13G
Jul 08, 2022
blackrock inc.
1.8%
3,960,718
SC 13G
Feb 03, 2022
blackrock inc.
7.1%
15,476,683
SC 13G/A
Feb 02, 2021
blackrock inc.
5.5%
11,575,051
SC 13G

Recent SEC filings of iBio Inc

View All Filings
Date Filed Form Type Document
Apr 09, 2024
SC 13G/A
Major Ownership Report
Apr 08, 2024
SC 13G
Major Ownership Report
Apr 05, 2024
SC 13G
Major Ownership Report
Apr 04, 2024
D
D
Apr 01, 2024
SC 13G
Major Ownership Report
Apr 01, 2024
8-K
Current Report
Feb 26, 2024
8-K
Current Report
Feb 21, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
10-Q
Quarterly Report

Peers (Alternatives to iBio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

iBio Inc News

Latest updates
Defense World35 hours ago
MarketWatch10 Apr 202409:30 pm
MarketWatch09 Apr 202409:30 pm
Seeking Alpha27 Mar 202407:00 am
GlobeNewswire26 Mar 202407:00 am
Yahoo Finance4 months ago

iBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue----1,80016884.004917657054101,12096.0031410879552765145.0091.0078.00153
Gross Profit---46.001,89555.0017172.00272494303-10.00---------
Operating Expenses-12.7%4,4965,15310,4538,5887,2315,3099,5117,4758,0397,2273,5914,0743,4693,9634,8484,2974,6663,9954,0373,571-
  S&GA Expenses-16.5%2,9613,5476,8915,3165,3724,1756,1675,3135,6655,3652,9932,9792,5812,9863,2242,8443,3932,8712,9952,605-
  R&D Expenses-4.4%1,5351,6063,5623,2721,8591,1343,3442,1622,3741,8625981,0958889771,6241,4531,2731,1241,042966-
Interest Expenses30.8%34.0026.00310--610613612615614615616615620474474476476478478-
Net Income-42.9%-8,211-5,746-17,054-12,390-11,920-8,940118-7,661-8,131-7,534-3,536-4,676-3,764-4,464-4,502-4,223-4,470-4,399-8,244-3,962-
Net Income Margin0%-25.65*-25.65*-24.51*-13.03*-18.84*-12.04*-9.79*-8.95*-10.24*------------
Free Cashflow11.9%-4,706-5,340-14,933-6,588-12,819-10,470-9,740-8,342-9,413------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-9.7%34.0038.0041.0044.0052.0085.0099.0011512614414714314511794.0042.0036.0035.0031.0036.0040.00
  Current Assets-14.4%20.0023.0026.0027.0038.0064.0045.0060.0067.0090.0010510711185.0062.0010.004.002.005.0010.0014.00
    Cash Equivalents90.8%3.001.004.007.004.0016.0029.0040.0045.0063.0077.0085.0091.0078.0055.0010.004.002.004.009.0013.00
  Inventory-------4.003.002.001.000.00----------
  Net PPE-4.0%4.004.004.004.004.003.001.0035.0033.0010.009.006.005.004.004.003.003.003.0024.0025.0025.00
Liabilities1.5%25.0024.0026.0027.0033.0036.0036.0036.0036.0043.0038.0038.0038.0037.0038.0038.0037.0037.0028.0029.0029.00
  Current Liabilities4.1%22.0021.0022.0022.0028.0032.0030.008.008.008.007.006.006.005.005.006.005.005.003.004.004.00
Shareholder's Equity-30.4%9.0013.0015.0017.0019.0048.0063.0079.0091.0010110910510780.0057.004.00--2.007.0011.00
  Retained Earnings-2.8%-302-294-288-282-275-242-223-206-194-182-173-173-166-157-150-146-135-110-105-101-97.09
  Additional Paid-In Capital1.4%312308304300295291288286285283282278273238207151135108108108108
Shares Outstanding134.6%3.001.001.001.000.000.000.000.000.000.000.000.000.00--------
Minority Interest-----------0.02-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.000.00
Float-----5.00---120---222---14.00---7.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations11.9%-4,706-5,340-4,970-3,872-7,635-13,959-11,503-5,944-10,686-9,347-7,226-7,349-8,419-7,070-3,867-3,786-3,405-2,287-4,392-4,135-4,670
  Share Based Compensation-40.4%4567654461,5961,1271,2221,1791,2741,10382159637426535122063.0037.0068.0059.0049.0060.00
Cashflow From Investing-100.0%-50.00-6.008,241-1,25529.00477517-972-5,149-2,908-4,014-12,956-6,600-820-96.00-208-30.00-173-139-389
Cashflow From Financing62.0%4,0052,4722,7401,464-3,0441,141-10.00-10.00-6,017-88.002,9124,73835,08436,10149,75910,2875,146--50.00-50.002,410

IBIO Income Statement

2023-12-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues  $ 50 
Operating expenses:    
Research and development$ 1,535$ 2,7793,141$ 5,327
General and administrative2,9617,7946,50812,882
Total operating expenses4,49610,5739,64918,209
Operating loss(4,496)(10,573)(9,599)(18,209)
Other income (expense):    
Interest expense(34)(31)(60)(31)
Interest income424197140
Total other income81037109
Net loss attributable to iBio, Inc. from continuing operations(4,488)(10,563)(9,562)(18,100)
Net loss from continuing operations(4,488)(10,563)(9,562)(18,100)
Loss from discontinued operations(3,723)(22,990)(4,395)(33,583)
Net loss(8,211)(33,553)(13,957)(51,683)
Comprehensive loss:    
Consolidated net loss(8,211)(33,553)(13,957)(51,683)
Other comprehensive loss - unrealized loss on debt securities 56 46
Comprehensive loss$ (8,211)$ (33,497)$ (13,957)$ (51,637)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations$ (2.42)$ (21.54)$ (6.27)$ (38.82)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations(2.42)(21.54)(6.27)(38.82)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations(2.00)(46.89)(2.88)(72.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations(2.00)(46.89)(2.88)(72.03)
Loss per common share attributable to iBio, Inc. stockholders - basic - total(4.42)(68.43)(9.15)(110.85)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total$ (4.42)$ (68.43)$ (9.15)$ (110.85)
Weighted-average common shares outstanding - basic1,8564901,525466
Weighted-average common shares outstanding - diluted1,8564901,525466

IBIO Balance Sheet

2023-12-31
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 2,788,000$ 4,301,000
Restricted cash1,057,0003,025,000
Subscription receivable 204,000
Prepaid expenses and other current assets894,000664,000
Current assets held for sale14,960,00018,065,000
Total Current Assets19,699,00026,259,000
Restricted cash215,000253,000
Promissory note receivable and accrued interest1,750,0001,706,000
Net finance lease ROU assets475,000610,000
Operating lease right-of-use asset2,565,0002,722,000
Fixed assets, net of accumulated depreciation3,890,0004,219,000
Intangible assets, net of accumulated amortization5,378,0005,388,000
Security deposits50,00050,000
Total Assets34,022,00041,207,000
Current liabilities:  
Accounts payable1,859,0001,849,000
Accrued expenses3,757,0004,034,000
Finance lease obligations - current portion285,000272,000
Operating lease obligation - current portion412,000389,000
Equipment financing payable - current portion168,000160,000
Insurance premium financing payable481,000 
Term note payable - net of deferred financing costs12,655,00012,937,000
Current liabilities related to assets held for sale1,936,0001,941,000
Total Current Liabilities21,553,00021,582,000
Finance lease obligations - net of current portion205,000351,000
Operating lease obligation - net of current portion2,912,0003,125,000
Equipment financing payable - net of current portion155,000241,000
Accrued expenses - noncurrent 527,000
Total Liabilities24,825,00025,826,000
Stockholders' Equity  
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at December 31, 2023 and June 30, 2023; 0 and 0 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively
Common Stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2023 and June 30, 2023; 3,243,725 and 1,015,505 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively30,00020,000
Additional paid-in capital312,064,000304,301,000
Accumulated deficit(302,897,000)(288,940,000)
Total Stockholders' Equity9,197,00015,381,000
Total Liabilities and Stockholders' Equity$ 34,022,000$ 41,207,000
IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
 CEO
 WEBSITEibioinc.com
 INDUSTRYBiotechnology
 EMPLOYEES105

iBio Inc Frequently Asked Questions


What is the ticker symbol for iBio Inc? What does IBIO stand for in stocks?

IBIO is the stock ticker symbol of iBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iBio Inc (IBIO)?

As of Fri Apr 12 2024, market cap of iBio Inc is 7.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IBIO stock?

You can check IBIO's fair value in chart for subscribers.

What is the fair value of IBIO stock?

You can check IBIO's fair value in chart for subscribers. The fair value of iBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iBio Inc a good stock to buy?

The fair value guage provides a quick view whether IBIO is over valued or under valued. Whether iBio Inc is cheap or expensive depends on the assumptions which impact iBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBIO.

What is iBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, IBIO's PE ratio (Price to Earnings) is -0.26 and Price to Sales (PS) ratio is 2.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on iBio Inc's stock?

In the past 10 years, iBio Inc has provided -0.334 (multiply by 100 for percentage) rate of return.